Header Logo

Connection

Usman Baber to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Treatment Outcome.
Usman Baber
Connection Strength
6.954
Treatment Outcome
  1. Inflammatory Potential and Risk?Prediction After PCI in High?Bleeding?Risk?Patients. JACC Cardiovasc Interv. 2024 Feb 12; 17(3):356-358.
    View in: PubMed
    Score: 0.144
  2. Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? Med Clin North Am. 2024 May; 108(3):539-551.
    View in: PubMed
    Score: 0.143
  3. Impact of Frailty on Outcomes in Patients Who Underwent Transcatheter Mitral Valve Replacement. Am J Cardiol. 2023 09 15; 203:301-303.
    View in: PubMed
    Score: 0.138
  4. Impact of Obesity on Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair With MitraClip. Am J Cardiol. 2023 Aug 01; 200:47-49.
    View in: PubMed
    Score: 0.137
  5. Switching Between Intravenous and Oral P2Y12 Inhibition: Easier Said Than Done. JACC Cardiovasc Interv. 2023 01 09; 16(1):47-49.
    View in: PubMed
    Score: 0.133
  6. Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More. JACC Cardiovasc Interv. 2022 06 13; 15(11):1164-1166.
    View in: PubMed
    Score: 0.128
  7. Coronary Artery Calcification and Mortality After Revascularization: Look Beyond the Heart. JACC Cardiovasc Interv. 2022 01 24; 15(2):205-207.
    View in: PubMed
    Score: 0.124
  8. The 5W1H in antiplatelet monotherapy after percutaneous coronary intervention: what, who, where, when, why, and how? Rev Esp Cardiol (Engl Ed). 2022 Feb; 75(2):115-118.
    View in: PubMed
    Score: 0.122
  9. Hemoglobin A1c and Cardiovascular Outcomes Following Percutaneous Coronary Intervention: Insights From a Large Single-Center Registry. JACC Cardiovasc Interv. 2021 02 22; 14(4):388-397.
    View in: PubMed
    Score: 0.117
  10. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020 10 01; 41(37):3533-3545.
    View in: PubMed
    Score: 0.114
  11. Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go? JACC Cardiovasc Interv. 2020 10 12; 13(19):2263-2265.
    View in: PubMed
    Score: 0.113
  12. Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY. Catheter Cardiovasc Interv. 2021 01 01; 97(1):63-71.
    View in: PubMed
    Score: 0.111
  13. Ventricular Fibrillation Associated With Coronary Plaque Erosion Detected by Optical Coherence Tomography. JACC Cardiovasc Interv. 2020 01 13; 13(1):e5-e7.
    View in: PubMed
    Score: 0.108
  14. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 07; 12(7):e007734.
    View in: PubMed
    Score: 0.104
  15. Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. Curr Opin Cardiol. 2019 07; 34(4):315-322.
    View in: PubMed
    Score: 0.104
  16. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
    View in: PubMed
    Score: 0.101
  17. The Challenge of Diabetes Mellitus in the Contemporary Percutaneous Coronary Intervention Era: Are We Making Progress? JACC Cardiovasc Interv. 2018 12 24; 11(24):2477-2479.
    View in: PubMed
    Score: 0.101
  18. Defining PCI complexity in the contemporary DES era: Clarity or confusion? Int J Cardiol. 2018 10 01; 268:94-95.
    View in: PubMed
    Score: 0.099
  19. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). Circ Cardiovasc Interv. 2018 03; 11(3):e006144.
    View in: PubMed
    Score: 0.095
  20. Predicting risk for bleeding after PCI: Another step in the right direction but work remains. Int J Cardiol. 2018 03 01; 254:45-46.
    View in: PubMed
    Score: 0.095
  21. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv. 2017 10 23; 10(20):2017-2025.
    View in: PubMed
    Score: 0.091
  22. Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough. Cardiology. 2017; 138(2):73-75.
    View in: PubMed
    Score: 0.091
  23. Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. Am Heart J. 2017 Jun; 188:73-81.
    View in: PubMed
    Score: 0.089
  24. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Am Heart J. 2016 Dec; 182:125-134.
    View in: PubMed
    Score: 0.086
  25. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. Coron Artery Dis. 2016 Sep; 27(6):442-8.
    View in: PubMed
    Score: 0.086
  26. Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. Eur Heart J. 2016 Dec 07; 37(46):3440-3447.
    View in: PubMed
    Score: 0.086
  27. Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction. Interv Cardiol Clin. 2016 10; 5(4):481-495.
    View in: PubMed
    Score: 0.085
  28. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovasc Interv. 2016 07 11; 9(13):1349-57.
    View in: PubMed
    Score: 0.085
  29. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):28-38.
    View in: PubMed
    Score: 0.082
  30. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost. 2013 Jul; 110(1):118-23.
    View in: PubMed
    Score: 0.068
  31. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar; 5(3 Suppl):S53-61.
    View in: PubMed
    Score: 0.063
  32. Acute coronary syndromes: Antithrombotics in ACS--moving beyond unfractionated heparin. Nat Rev Cardiol. 2011 Sep 27; 8(11):613-4.
    View in: PubMed
    Score: 0.061
  33. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011 Oct 04; 58(15):1569-77.
    View in: PubMed
    Score: 0.061
  34. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
    View in: PubMed
    Score: 0.054
  35. Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial. EuroIntervention. 2025 May 16; 21(10):550-559.
    View in: PubMed
    Score: 0.039
  36. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024 Sep 07; 404(10456):937-948.
    View in: PubMed
    Score: 0.037
  37. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024 Jul 23; 150(4):317-335.
    View in: PubMed
    Score: 0.037
  38. Reply: Decoding Ticagrelor Dyspnea: Central Apnea Screening Before Drug Discontinuation. JACC Cardiovasc Interv. 2024 Feb 12; 17(3):452-453.
    View in: PubMed
    Score: 0.036
  39. Prognostic impact of peripheral artery disease in patients with and without high bleeding risk undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(3):425-434.
    View in: PubMed
    Score: 0.036
  40. Prognostic impact of in-stent restenosis in normal weight, overweight, and obese patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(2):260-267.
    View in: PubMed
    Score: 0.036
  41. Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2023 11 16; 383:e077848.
    View in: PubMed
    Score: 0.035
  42. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2023 10 23; 16(20):2514-2524.
    View in: PubMed
    Score: 0.035
  43. Timing and Predictors of Myocardial Infarction or Stent Thrombosis in High-Bleeding Risk Patients Undergoing PCI. JACC Cardiovasc Interv. 2023 06 26; 16(12):1558-1560.
    View in: PubMed
    Score: 0.034
  44. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium. Circulation. 2023 06 20; 147(25):1933-1944.
    View in: PubMed
    Score: 0.034
  45. P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. J Am Coll Cardiol. 2023 02 14; 81(6):537-552.
    View in: PubMed
    Score: 0.034
  46. Educational Experience of Interventional?Cardiology Fellows in the United States?and Canada. JACC Cardiovasc Interv. 2023 02 13; 16(3):247-257.
    View in: PubMed
    Score: 0.034
  47. Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease. Catheter Cardiovasc Interv. 2023 02; 101(3):511-519.
    View in: PubMed
    Score: 0.033
  48. New Criteria to Identify Patients at Higher Risk for Cardiovascular Complications After Percutaneous Coronary Intervention. Am J Cardiol. 2023 02 15; 189:22-30.
    View in: PubMed
    Score: 0.033
  49. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention. 2022 Dec 02; 18(11):e897-e909.
    View in: PubMed
    Score: 0.033
  50. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. JACC Cardiovasc Interv. 2022 10 10; 15(19):1948-1960.
    View in: PubMed
    Score: 0.033
  51. Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). Am J Cardiol. 2022 06 01; 172:73-80.
    View in: PubMed
    Score: 0.032
  52. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circ Cardiovasc Interv. 2022 04; 15(4):e009495.
    View in: PubMed
    Score: 0.031
  53. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention. 2022 Mar 18; 17(16):1330-1339.
    View in: PubMed
    Score: 0.031
  54. Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. Can J Cardiol. 2022 06; 38(6):792-800.
    View in: PubMed
    Score: 0.031
  55. Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. Am J Cardiol. 2022 04 01; 168:47-54.
    View in: PubMed
    Score: 0.031
  56. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022 02 14; 15(3):282-293.
    View in: PubMed
    Score: 0.031
  57. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021 12 01; 42(45):4683-4693.
    View in: PubMed
    Score: 0.031
  58. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021 12 01; 42(45):4624-4634.
    View in: PubMed
    Score: 0.031
  59. Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. JACC Cardiovasc Interv. 2021 11 22; 14(22):2447-2457.
    View in: PubMed
    Score: 0.031
  60. Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. Catheter Cardiovasc Interv. 2021 11 15; 98(6):E785-E795.
    View in: PubMed
    Score: 0.030
  61. Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. J Thromb Thrombolysis. 2022 Feb; 53(2):380-389.
    View in: PubMed
    Score: 0.030
  62. Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. J Thromb Thrombolysis. 2022 Jan; 53(1):20-29.
    View in: PubMed
    Score: 0.030
  63. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC Cardiovasc Interv. 2021 07 12; 14(13):1434-1446.
    View in: PubMed
    Score: 0.030
  64. Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheter Cardiovasc Interv. 2021 11 15; 98(6):E908-E917.
    View in: PubMed
    Score: 0.030
  65. Reply: Percutaneous Coronary Intervention Outcomes According to HbA1c Levels. JACC Cardiovasc Interv. 2021 05 24; 14(10):1159-1160.
    View in: PubMed
    Score: 0.030
  66. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. JACC Cardiovasc Interv. 2021 02 22; 14(4):444-456.
    View in: PubMed
    Score: 0.029
  67. Comparison of the effect of Morphine and Fentanyl in patients with acute coronary syndrome receiving Ticagrelor - The COMET (Comparison Morphine, Fentayl and Ticagrelor) randomized controlled trial. Int J Cardiol. 2021 05 01; 330:1-6.
    View in: PubMed
    Score: 0.029
  68. Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI. JACC Cardiovasc Interv. 2020 12 28; 13(24):2882-2892.
    View in: PubMed
    Score: 0.029
  69. A sex paradox in clinical outcomes following complex percutaneous coronary intervention. Int J Cardiol. 2021 04 15; 329:67-73.
    View in: PubMed
    Score: 0.029
  70. Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021 06 01; 97(7):E936-E944.
    View in: PubMed
    Score: 0.029
  71. Side branch fractional flow reserve after provisional stenting of calcified bifurcation lesions: The ORBID-FFR study. Catheter Cardiovasc Interv. 2021 10; 98(4):658-668.
    View in: PubMed
    Score: 0.028
  72. Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. Catheter Cardiovasc Interv. 2021 04 01; 97(5):E704-E715.
    View in: PubMed
    Score: 0.028
  73. Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. Int J Cardiol. 2021 01 01; 322:65-69.
    View in: PubMed
    Score: 0.028
  74. Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial. EuroIntervention. 2020 Jun 25; 16(3):218-224.
    View in: PubMed
    Score: 0.028
  75. Procedural and 1-year clinical outcomes of orbital atherectomy for treatment of coronary in-stent restenosis: A single-center, retrospective study. Catheter Cardiovasc Interv. 2021 02 15; 97(3):E280-E287.
    View in: PubMed
    Score: 0.028
  76. Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Cardiovasc Res. 2020 06 01; 116(7):e70-e72.
    View in: PubMed
    Score: 0.028
  77. One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. Catheter Cardiovasc Interv. 2021 06 01; 97(7):1341-1351.
    View in: PubMed
    Score: 0.028
  78. Impact of renal function on the immediate and long-term outcomes of percutaneous recanalization of coronary chronic total occlusions: A systematic review and meta-analysis. Int J Cardiol. 2020 Oct 15; 317:200-206.
    View in: PubMed
    Score: 0.028
  79. 1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. Cardiovasc Revasc Med. 2020 12; 21(12):1542-1547.
    View in: PubMed
    Score: 0.028
  80. Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry. Catheter Cardiovasc Interv. 2021 01 01; 97(1):E26-E33.
    View in: PubMed
    Score: 0.028
  81. Comparison of One-Year Outcomes in Patients >75 Versus =75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). Am J Cardiol. 2020 07 15; 127:1-8.
    View in: PubMed
    Score: 0.028
  82. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study. J Am Heart Assoc. 2020 04 21; 9(8):e015865.
    View in: PubMed
    Score: 0.028
  83. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. JACC Cardiovasc Interv. 2020 04 13; 13(7):820-830.
    View in: PubMed
    Score: 0.028
  84. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention. 2020 Apr 03; 15(18):e1605-e1614.
    View in: PubMed
    Score: 0.027
  85. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ Cardiovasc Interv. 2020 04; 13(4):e008226.
    View in: PubMed
    Score: 0.027
  86. Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheter Cardiovasc Interv. 2021 04 01; 97(5):797-804.
    View in: PubMed
    Score: 0.027
  87. Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. Catheter Cardiovasc Interv. 2020 08; 96(2):298-308.
    View in: PubMed
    Score: 0.027
  88. Association between age and readmission after percutaneous coronary intervention for acute myocardial infarction. Heart. 2020 10; 106(20):1595-1603.
    View in: PubMed
    Score: 0.027
  89. Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):E278-E286.
    View in: PubMed
    Score: 0.027
  90. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 03 17; 141(11):891-901.
    View in: PubMed
    Score: 0.027
  91. The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. Catheter Cardiovasc Interv. 2020 07; 96(1):198-207.
    View in: PubMed
    Score: 0.027
  92. 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. Int J Cardiol. 2020 05 15; 307:17-23.
    View in: PubMed
    Score: 0.027
  93. The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial. Catheter Cardiovasc Interv. 2020 12; 96(7):E688-E694.
    View in: PubMed
    Score: 0.027
  94. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol. 2020 Jun; 109(6):725-734.
    View in: PubMed
    Score: 0.027
  95. Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. JACC Cardiovasc Interv. 2019 12 23; 12(24):2528-2537.
    View in: PubMed
    Score: 0.027
  96. Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. Catheter Cardiovasc Interv. 2020 10 01; 96(4):793-801.
    View in: PubMed
    Score: 0.027
  97. Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):558-564.
    View in: PubMed
    Score: 0.026
  98. Reply: DAPT Cessation and MACE in Elderly Patients: What Is the Optimal Regimen and Duration? JACC Cardiovasc Interv. 2019 08 26; 12(16):1627-1628.
    View in: PubMed
    Score: 0.026
  99. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). Eur Heart J. 2019 07 01; 40(25):2070-2085.
    View in: PubMed
    Score: 0.026
  100. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. J Thromb Thrombolysis. 2019 Jul; 48(1):42-51.
    View in: PubMed
    Score: 0.026
  101. Stent Expansion and Endothelial Shear Stress in Bifurcation Lesions. Circ Cardiovasc Interv. 2019 06; 12(6):e007911.
    View in: PubMed
    Score: 0.026
  102. Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2020 04 01; 95(5):885-892.
    View in: PubMed
    Score: 0.026
  103. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovasc Interv. 2019 05 27; 12(10):983-992.
    View in: PubMed
    Score: 0.026
  104. Procedural and one-year outcomes of patients treated with orbital and rotational atherectomy with mechanistic insights from optical coherence tomography. EuroIntervention. 2019 Apr 20; 14(17):1760-1767.
    View in: PubMed
    Score: 0.026
  105. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 04; 12(4):e007133.
    View in: PubMed
    Score: 0.026
  106. Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 15; 123(12):1941-1948.
    View in: PubMed
    Score: 0.026
  107. Frequency of 30-day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock. Catheter Cardiovasc Interv. 2019 Aug 01; 94(2):E67-E77.
    View in: PubMed
    Score: 0.025
  108. Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 02; 12(2):e007311.
    View in: PubMed
    Score: 0.025
  109. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.
    View in: PubMed
    Score: 0.025
  110. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheter Cardiovasc Interv. 2019 Jul 01; 94(1):53-60.
    View in: PubMed
    Score: 0.025
  111. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clin Res Cardiol. 2019 Jun; 108(6):643-650.
    View in: PubMed
    Score: 0.025
  112. Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. Can J Cardiol. 2019 02; 35(2):199-207.
    View in: PubMed
    Score: 0.025
  113. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018 12 07; 39(46):4101-4108.
    View in: PubMed
    Score: 0.025
  114. Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheter Cardiovasc Interv. 2019 05 01; 93(6):1124-1131.
    View in: PubMed
    Score: 0.025
  115. Predictors of side branch compromise in calcified bifurcation lesions treated with orbital atherectomy. Catheter Cardiovasc Interv. 2019 07 01; 94(1):45-52.
    View in: PubMed
    Score: 0.025
  116. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019 02 15; 93(3):E112-E119.
    View in: PubMed
    Score: 0.025
  117. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018 10 08; 11(19):1969-1978.
    View in: PubMed
    Score: 0.025
  118. Intravascular Brachytherapy for the Management of Repeated Multimetal-Layered Drug-Eluting Coronary Stent Restenosis. Circ Cardiovasc Interv. 2018 10; 11(10):e006832.
    View in: PubMed
    Score: 0.025
  119. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial. Am Heart J. 2018 11; 205:63-69.
    View in: PubMed
    Score: 0.025
  120. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). Am J Cardiol. 2018 11 15; 122(10):1638-1646.
    View in: PubMed
    Score: 0.025
  121. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Cardiovasc Ther. 2018 Oct; 36(5):e12457.
    View in: PubMed
    Score: 0.024
  122. 1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry. JACC Cardiovasc Interv. 2018 01 08; 11(1):1-12.
    View in: PubMed
    Score: 0.024
  123. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. JACC Cardiovasc Interv. 2018 01 08; 11(1):53-65.
    View in: PubMed
    Score: 0.024
  124. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can J Cardiol. 2018 03; 34(3):319-329.
    View in: PubMed
    Score: 0.023
  125. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2018 01 08; 11(1):68-76.
    View in: PubMed
    Score: 0.023
  126. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.023
  127. Asymptomatic Large Thrombus Formation in Drug-Eluting Stent 2 Days After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patient. JACC Cardiovasc Interv. 2017 12 11; 10(23):2461-2463.
    View in: PubMed
    Score: 0.023
  128. Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost. 2017 10 05; 117(10):1981-1988.
    View in: PubMed
    Score: 0.023
  129. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 08 01; 2(8):855-862.
    View in: PubMed
    Score: 0.023
  130. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. Sci Rep. 2017 08 01; 7(1):7001.
    View in: PubMed
    Score: 0.023
  131. Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1016-1026.
    View in: PubMed
    Score: 0.023
  132. Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. Catheter Cardiovasc Interv. 2018 04 01; 91(5):859-866.
    View in: PubMed
    Score: 0.023
  133. Mid-term outcomes of consecutive 998 cases of coronary atherectomy in contemporary clinical practice. J Interv Cardiol. 2017 Aug; 30(4):331-337.
    View in: PubMed
    Score: 0.023
  134. Percutaneous Coronary Intervention Outcomes in Very Elderly Patients From a Single Large-Volume Tertiary Care Center, Specifically Focusing on Nonagenarians. JACC Cardiovasc Interv. 2017 06 26; 10(12):1273-1274.
    View in: PubMed
    Score: 0.023
  135. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. Int J Cardiol. 2017 Sep 15; 243:132-139.
    View in: PubMed
    Score: 0.022
  136. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.022
  137. An Algorithm for the Use of Embolic Protection During Atherectomy for Femoral Popliteal Lesions. JACC Cardiovasc Interv. 2017 02 27; 10(4):403-410.
    View in: PubMed
    Score: 0.022
  138. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.022
  139. Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. J Am Coll Cardiol. 2016 Dec 27; 68(25):2733-2744.
    View in: PubMed
    Score: 0.022
  140. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials. Int J Cardiol. 2017 Mar 01; 230:310-318.
    View in: PubMed
    Score: 0.022
  141. Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 10 24; 9(20):2124-2133.
    View in: PubMed
    Score: 0.022
  142. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 09 26; 9(18):1890-901.
    View in: PubMed
    Score: 0.022
  143. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):E217-E225.
    View in: PubMed
    Score: 0.022
  144. Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes. Atherosclerosis. 2016 11; 254:42-51.
    View in: PubMed
    Score: 0.021
  145. Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. J Thromb Thrombolysis. 2016 Aug; 42(2):186-96.
    View in: PubMed
    Score: 0.021
  146. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovasc Interv. 2016 07 25; 9(14):1461-9.
    View in: PubMed
    Score: 0.021
  147. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):629-637.
    View in: PubMed
    Score: 0.021
  148. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. JACC Cardiovasc Interv. 2016 05 23; 9(10):1036-46.
    View in: PubMed
    Score: 0.021
  149. Plaque Morphology Predictors of Side Branch Occlusion After Main Vessel Stenting in Coronary Bifurcation Lesions: Optical Coherence Tomography Imaging Study. JACC Cardiovasc Interv. 2016 Apr 25; 9(8):862-865.
    View in: PubMed
    Score: 0.021
  150. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016 Apr 11; 9(7):674-84.
    View in: PubMed
    Score: 0.021
  151. Plaque morphology predictors of side branch occlusion after provisional stenting in coronary bifurcation lesion: Results of optical coherence tomography bifurcation study (ORBID). Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):259-268.
    View in: PubMed
    Score: 0.021
  152. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 01; 117(11):1703-13.
    View in: PubMed
    Score: 0.021
  153. Efficacy and safety of routine thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An updated systematic review and meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv. 2016 Mar; 87(4):650-60.
    View in: PubMed
    Score: 0.020
  154. Meta-Analysis of Radial Versus Femoral Access for Percutaneous Coronary Interventions in Non-ST-Segment Elevation Acute Coronary Syndrome. Am J Cardiol. 2016 Jan 15; 117(2):172-8.
    View in: PubMed
    Score: 0.020
  155. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study. Catheter Cardiovasc Interv. 2016 Mar; 87(4):703-9.
    View in: PubMed
    Score: 0.020
  156. Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. Circ Cardiovasc Interv. 2015 Aug; 8(8):e002475.
    View in: PubMed
    Score: 0.020
  157. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 15; 116(6):845-52.
    View in: PubMed
    Score: 0.020
  158. Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015 Jun; 8(7):937-45.
    View in: PubMed
    Score: 0.020
  159. Optical coherence tomography assessment of the mechanistic effects of rotational and orbital atherectomy in severely calcified coronary lesions. Catheter Cardiovasc Interv. 2015 Nov 15; 86(6):1024-32.
    View in: PubMed
    Score: 0.020
  160. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). Am J Cardiol. 2015 Jul 01; 116(1):37-42.
    View in: PubMed
    Score: 0.019
  161. Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes. Am Heart J. 2015 Jul; 170(1):180-6.
    View in: PubMed
    Score: 0.019
  162. Comparison of provisional 1-stent and 2-stent strategies in diabetic patients with true bifurcation lesions: the EES bifurcation study. J Invasive Cardiol. 2014 Dec; 26(12):619-23.
    View in: PubMed
    Score: 0.019
  163. The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. Eur Heart J Cardiovasc Imaging. 2015 Jan; 16(1):81-7.
    View in: PubMed
    Score: 0.019
  164. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention. 2014 Jul; 10(3):312-9.
    View in: PubMed
    Score: 0.018
  165. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013 Dec 07; 382(9908):1879-88.
    View in: PubMed
    Score: 0.017
  166. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013 Nov 23; 382(9906):1714-22.
    View in: PubMed
    Score: 0.017
  167. Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization. Catheter Cardiovasc Interv. 2013 Nov 15; 82(6):855-68.
    View in: PubMed
    Score: 0.017
  168. The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv. 2014 Jan 01; 83(1):148-53.
    View in: PubMed
    Score: 0.017
  169. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging. 2012 May; 5(5):540-9.
    View in: PubMed
    Score: 0.016
  170. Female gender and mortality after percutaneous coronary intervention: results from a large registry. Catheter Cardiovasc Interv. 2012 Oct 01; 80(4):514-21.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.